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Background: The RNA-binding protein tristetraprolin (TTP) participates in normal post-transcriptional control of
cytokine and chemokine gene expression, dysregulation of which contributes to the HIV-associated neurocognitive
disorders. Transcriptional and post-transcriptional regulation of TTP has been described, including regulation by
microRNA-29a. In the simian immunodeficiency virus (SIV) model of HIV CNS disease, control of cytokine/chemokine
expression coincides with the end of acute phase infection. This control is lost during progression to disease. In this
study, we assessed TTP regulation and association with cytokine regulation in the brain during SIV infection.
Results: Quantitation of TTP expression over the course of SIV infection revealed downregulation of TTP during
acute infection, maintenance of relatively low levels during asymptomatic phase, and increased expression only
during late-stage CNS disease, particularly in association with severe disease. The ability of miR-29a to regulate TTP
was confirmed, and evidence for additional miRNA targeters of TTP was found. However, increased miR-29a
expression in brain was not found to be significantly negatively correlated with TTP. Similarly, increased TTP during
late-stage disease was not associated with lower cytokine expression.
Conclusions: TTP expression is regulated during SIV infection of the CNS. The lack of significant negative
correlation of miR-29a and TTP expression levels suggests that while miR-29a may contribute to TTP regulation,
additional factors are involved. Reduced TTP expression during acute infection is consistent with increased cytokine
production during this phase of infection, but the increases in TTP observed during late-stage infection were
insufficient to halt runaway cytokine levels. While antisense inhibitors of the post-transcriptional targeters of TTP
identified here could conceivably be used further to augment TTP regulation of cytokines, it is possible that high
levels of TTP are undesirable. Additional research is needed to characterize members of the miRNA/TTP/cytokine
regulatory network and identify nodes that may be best targeted therapeutically to ameliorate the effects of
chronic inflammation in retrovirus-associated CNS disease.
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HIV-associated neurocognitive disorderBackground
The advent of effective antiretroviral therapy for HIV-1 in
the mid-1990s dramatically improved life expectancy and
quality [1]. However, as individuals live longer with HIV,
the HIV-associated neurocognitive disorders (HAND) re-
main a growing problem [2,3]. HAND severity ranges* Correspondence: kwitwer1@jhmi.edu
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reproduction in any medium, provided the orfrom asymptomatic neurocognitive impairment to minor
motor/cognitive disorder to HIV-associated dementia [4],
and its effects span several neurocognitive domains, including
attention/working memory, motor skills, and executive
functions [5,6].
The growing prevalence of HAND dictates a need to
understand the underlying disease mechanism, which have
not been fully elucidated but are likely multifactorial.
Neurotoxicity of viral products [7,8] and prolonged expos-
ure to inflammatory cytokines/chemokines are probable
causes [9-11]. Innate immune responses during acuteThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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disposition to disease [12,13]. Because longitudinal moni-
toring of the central nervous system (CNS) is difficult or
impossible in human cohorts, our group developed a sim-
ian immunodeficiency virus (SIV) macaque model of HIV
CNS pathogenesis [14,15]. In this model, pigtailed ma-
caques (Macaca nemestrina) are dual inoculated with
SIV/17E-Fr, a neurovirulent clone, and SIV/ΔB670, an im-
munosuppressive swarm. An initial acute phase, like that
seen in HIV, lasts for the first 10-14 days post infection
(dpi), with many measures of innate immune response
peaking around 7 dpi [12]. This is followed by a latent or
“asymptomatic” phase. Pronounced CD4+ T cell depletion
and motor deficits appear by approximately 35 days dpi
and are monitored until 84 dpi, by which time more than
90% of infected macaques have developed CNS disease
and AIDS [15]. Patterns of cytokine expression during SIV
infection suggest that, at terminal stages of disease, high
and sustained cytokine levels contribute to neurodegener-
ative pathologies. Transient acute phase cytokine expres-
sion may itself cause lasting damage or set the stage for
neurodegeneration. Accordingly, brain cytokine regulation
is of central importance in CNS disease progression.
Tristetraprolin (TTP, also known as zinc finger pro-
tein 36 homolog, ZFP36) has been characterized as an
anti-inflammatory and anticarcinogenic protein that is
also involved in differentiation processes [16,17]. TTP
is thought to act primarily through post-transcriptional
regulation of messenger RNA [18,19]. TTP binds to
and destabilizes transcripts with 3′ untranslated re-
gions (3′ UTRs) that contain AU-rich elements (AREs)
[20-22], including those of CCL2, IL-6, IL-10, TNF-α,
iNOS, and many other inflammatory mediators. Post-
transcriptionally, TTP activity is regulated by post-
translational phosphorylation, and a cellular microRNA
(miRNA) has been reported to modulate TTP abun-
dance [23,24]. miRNAs are short, single-stranded RNA
molecules—often 22-23 nucleotides in length—that
regulate host and viral gene expression [25-28]. Incorpo-
rated into the cytosolic RNA-induced silencing complex,
miRNAs bind transcripts through partially complementary
sequences known as miRNA recognition elements (MRE),
usually located in the 3′ UTR of the target transcript
[25,26]. Subsequent regulation can be achieved by tran-
script cleavage and degradation, inhibition of translation,
and cellular sequestration of transcripts.
Because TTP has been reported to regulate many cyto-
kines that we previously observed to be coordinately regu-
lated in SIV infection [12], and since miRNAs have
various associations with CNS disease [13,29-32], we in-
vestigated the expression of TTP and potentially related
miRNAs in our HIV CNS disease model. We then queried
the role of TTP in cytokine regulation during SIV disease,
as well as the influence of miRNA expression on TTPlevels. We report here that TTP is differentially regulated
during the course of SIV infection and that acute phase
downregulation of TTP is mechanistically consistent with
increased cytokine levels recorded during this phase.
However, during the general dysregulation of late-stage
disease, increased expression of TTP is apparently insuffi-
cient to halt damaging levels of cytokine production. We
also confirm that miR-29a can indeed regulate the TTP 3′
UTR, but that consideration of other factors is needed to
explain TTP modulation in the CNS. Finally, we present
evidence for several additional miRNA members of a com-
plex interaction network governing TTP, miRNA, and
cytokine expression.
Results
TTP mRNA is differentially expressed during
viral pathogenesis
TTP mRNA in SIV-infected brain (thalamus) was quanti-
fied during several stages of SIV infection in macaques
(Figure 1A), comparing control, uninfected animals with
acute (4, 7, 10 dpi), persistent/asymptomatic (14, 21 dpi),
and late-stage infection (42, 56, 84 dpi). Thalamus was
chosen because SIV replication occurs at high levels in
thalamus and SIV lesions are observed most frequently in
thalamus, basal ganglia, and parietal cortex [14]. The TTP
transcript is downregulated relative to uninfected controls
during acute infection (p < 0.01, Kruskal Wallis test with
Tukey’s post-test) and, in most individuals, appears to be
present at a decreased level throughout infection. How-
ever, a trend towards recovery to control levels is seen at
the end of acute phase, when TTP levels are no longer
significantly different from control, while TTP abundance
is significantly lower in acute versus late stage disease. As
revealed by assessment of CNS disease severity at specific
time points post-infection (Figure 1B), this difference is
driven by the production of larger amounts of TTP tran-
script by individuals that developed severe CNS disease.
Indeed, during late-stage infection, subjects that had se-
vere or moderate CNS disease had significantly more TTP
mRNA than those with no or only mild disease (p =
0.0021, Mann Whitney test).
miR-29a targets the 3′UTR of TTP
Both RNA-binding proteins [33]—such as TTP—and
miRNAs are known to regulate transcripts, usually through
elements in the 3′ UTR. Moreover, miR-29a was previously
shown to target the TTP 3′ UTR directly [23]. We there-
fore examined miR-29a expression in SIV-infected brain to
determine whether this miRNA might play a role in regu-
lation of TTP during lentiviral infection and CNS disease.
Using in silico analyses that combined several miRNA
target prediction algorithms, we verified the previously
reported response of the TTP 3′ UTR to miR-29a [23]. In
a fluorescent reporter system comprising HEK-293 T cells
Figure 1 Tristetraprolin mRNA expression during SIV infection. TTP
was quantitated by TaqMan assay using total RNA isolated from
thalamus of control, uninfected (‘0’) or SIV-infected macaques at different
stages of infection and disease (A) and at the indicated number of days
post-inoculation (B). Data were normalized by delta-deltaCt method,
with 18S rRNA as the control, and graphed relative to the average
expression of the control group. Bars represent mean (A) or median
(B) fold change in each stage or at each time point. Shown for late-
stage infection (B), CNS disease severity as determined by pathology
examination is denoted by color: green = none, turquoise =mild,
blue =moderate, red = severe. Inset: data sorted by stage of infection.
Acute phase comprises days 4-10; persistent includes time points with
lower viral load and cytokine expression (14 and 21); late-stage disease
begins at day 42. ** denotes p < 0.01 by Kruskal-Wallis test with Dunn’s
multiple comparison test.
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constructs with or without the TTP 3′ UTR, miR-29a-me-
diated regulation of TTP was confirmed (Figure 2). Flow
cytometry showed a greater than two-fold downward shift
in the mean intensity of cells transfected with the TTP 3′
UTR construct compared with cells containing the GFP
vector alone, suggesting that HEK-293 T cells contain en-
dogenous factors, including but not necessarily limited tomiRNAs, that exert regulatory effects through the TTP 3′
UTR. Compared with the ratio of fluorescence of cells
containing the GFP-TTP- 3′ UTR construct versus GFP
vector alone, co-transfection with a miR-29a mimic, but
not a scrambled control RNA (“mimic control”), caused a
further decrease in mean fluorescence of cells transfected
with the 3′ UTR construct (Figure 2A), while neither miR-
29a mimic nor mimic control exerted significant effects on
the GFP-only construct. Together, these results confirmed
that miR-29a is among the regulatory molecules that target
the TTP 3′UTR. However, co-transfection of an antisense
miR-29a antagonist and the TTP UTR construct did not
result in a significant increase in mean fluorescence inten-
sity when compared with transfection of a control antagon-
ist or no antagonist (Figure 2A). This could be due to a
low endogenous level of miR-29a. Additionally or alterna-
tively, although exogenous miR-29a clearly enhances 3′
UTR-mediated suppression, additional miRNAs or other
factors are capable of enforcing suppression in a com-
monly used cell line, even during suppression of miR-29a.
Transfection of microRNAs into human macrophages
affects TTP levels
We next characterized the effects of miR-29a mimics and
inhibitors on TTP expression in cells of the monocyte/
macrophage lineage. Monocyte-derived macrophages were
chosen for two reasons. First, macrophages are central
actors in immune responses and viral replication and entry
into to the brain in our SIV encephalitis model as well
as in HIV-1 infection of brain. Second, previous work
indicated the involvement of macrophage TTP in regu-
lation of cytokines such as TNF-alpha [34-36]. Third,
miR-29 species are upregulated in macrophages during
differentiation [37] and in early SIV infection [38]. Flow
cytometry of macrophages that were co-transfected
with the GFP-TTP 3′UTR reporter vector and small
RNA molecules showed that a miR-29a mimic, but not
a control RNA, reduced mean fluorescence intensity by
20-70%, i.e. consistently, but with considerable inter-
donor variability (Figure 2B). As with the HEK-293 T
experiments, however, only a slight increase in fluores-
cence was seen upon transfection with a miR-29a anta-
gonist, suggesting redundancy of 3′ UTR-binding sites
in macrophages. We also performed an experiment in
which mimics and inhibitors of miR-29a were trans-
fected into primary macrophages without a reporter
vector to assess the effects of the miRNA on native
protein. Semi-quantitative analysis of Western immu-
noblots for native TTP protein revealed that transfec-
tion of miR-29a inhibited TTP production, whereas
anti-miR-29a resulted in a 4-fold increase of protein
(Additional file 1: Figure S1). We thus confirmed that
miR-29a is a regulator of TTP, including in the disease-
relevant setting of the macrophage.
Figure 2 miR-29a-mediated regulation through the TTP 3′ UTR. HEK-293 T cells (A) or monocyte-derived macrophages (B) were transfected
with reporter plasmids (GFP-TTP-3′ UTR or GFP empty vector), red fluorescent protein (RFP) transfection control, and small RNA molecules as
indicated (scrambled mimic control, miR-29a mimic, antagonist control, or miR-29a antagonist). 24 hours post-transfection, fluorescence of cells
transfected with reporter and empty vector were determined by flow cytometry. A) Exogenous miR-29a caused a significant reduction (***,
p < 0.0001 by t-test, p < 0.01 by ANOVA) in the normalized fluorescence ratio of HEK-293 T cells transfected with the GFP-TTP-3′ UTR construct vs.
GFP vector alone. B) Because of sample-to-sample variability, the consistent decrease in normalized GFP-TTP 3′UTR fluorescence in the presence
of exogenous miR-29a in macrophages approached but did not reach statistical significance as determined by ANOVA (p > 0.05). Error bars are
standard error of the mean.
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to SIV CNS disease
To assess the relationship of miR-29a and TTP in brain,
miR-29a levels were measured in thalamus in the SIV/
macaque model, spanning the course of viral pathogen-
esis. The mature human and pigtailed macaque miR-29a
sequences are 100% identical. Although there was an ap-
parent trend towards increasing miR-29a values during
infection, and group means were significantly different
(p < 0.01, Kruskal Wallis), relatively constant mean levels
of miR-29a were maintained at least through latent
infection, and in almost all animals, miR-29a abundance
was within two fold of the average of control, uninfected
animals (Figure 3). However, when compared with controls,
there were significant increases (p < 0.05 by Kruskal Wallis
test) in the group means of the 56 and 84 dpi late-stage
animals (as well as for all late-stage groups together).
There was also substantial variation within each group. As
with TTP mRNA levels, miR-29a expression tended to be
highest in animals with severe disease.
Relationship of miR-29a and TTP mRNA levels
An inverse correlation of miR-29a and TTP expression
might be expected in the case of an exclusive, classic
regulatory relationship of the miRNA with its target.
However, no significant correlation was found in our
model across time points (data not shown). Analyses fo-
cused on specific phases of infection (acute, persistent/
asymptomatic, and late-stage disease) similarly found
no negative correlations of miR-29a with TTP. As
noted, miR-29a and TTP levels were highest in late
stage disease, and a positive correlation (R = 0.58, datanot shown) was in fact observed between the two
analytes at 84 dpi.
Novel miRNA regulators of TTP
We sought to identify additional miRNA candidates for
TTP 3′ UTR regulation for three reasons. First, although
exogenous miR-29a inhibitors allowed greater produc-
tion of native TTP protein in macrophages (Additional
1: Figure S1), our reporter experiments in both 293 T
and primary macrophage culture indicated that miR-29a
was not the only regulator of the TTP 3′ UTR. Second,
as described, we did not observe an inverse relationship
of TTP and miR-29a levels in vivo, as one might expect
if miR-29a were a major physiologically relevant regu-
lator of TTP during SIV infection in brain. Third, rela-
tionships of TTP with additional miRNAs in more
complicated regulatory networks have been proposed in
the recent literature [39,40]. Three target prediction
algorithms were used to generate a list of candidate
miRNAs, which were ranked based upon the number of
predicting algorithms and the number of predicted
MREs in the 3′ UTR for each miRNA.
Among miRNAs detectable in brain (unpublished data),
there were approximately 50 candidates, and requiring at
least one perfect seed match narrowed the field to 18.
Interestingly, although miR-29a was predicted by one of
the programs (TargetScan), it did not appear to be the
strongest match by free energy criteria. The TTP MRE
seed match for miR-29a (or, indeed, for any miR-29 family
member) is highly conserved among primates, from hu-
man to marmoset. However, there is little interaction out-
side the seed region, with one potential G-C pairing and
Figure 3 Longitudinal expression of miR-29a in SIV-infected
brain. Expression of miR-29a was determined by miRNA stem-loop
RT-qPCR using the delta-deltaCt method with normalization to
snRNA U6 (similar results were obtained with normalization to the
geometric mean of multiple invariant miRNAs—data not shown).
Fold changes relative to the average of the control animals (‘0’) are
shown. Bars represent the mean at each time point. Color coding of
severity during late-stage infection is as described for Figure 1.
Statistical significance was assessed for each time point versus
control by Kruskal Wallis test with Dunn’s test for multiple
comparisons; * represents p < 0.05.
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(Figure 4A). As a result, target prediction algorithms that
considered interactions outside the seed region, but not site
conservation, did not necessarily return miR-29 as a TTP
interactor. According to TargetScan, which did predict
miR-29, the context score percentile for the interaction is
55 or 59 for 29a/c and 29b, respectively. miR-145 and miR-
155 target interactions had context scores of 91 and 42,
respectively (Figure 4A). In contrast, miR-361-3p had fourFigure 4 Novel interactions of miRNAs with TTP 3′ UTR elements. A) A
interaction, along with alignments for additional miR-29 family members a
(top) and miRNA (bottom) canonical base pairings are shown with ‘|’, while
Reduction in mean fluorescence intensity (MFI) of the TTP (ZFP36) 3′ UTR i
Error bars are standard error of the mean.predicted recognition elements in the TTP 3′ UTR that
were predicted by at least one program, including three
perfect seed matches (alignments not shown). Although
TargetScan context score percentiles for the human
sequences were 55, 65, and 71, the target sequences for
miR-361-3p were not well conserved, there was little or no
interaction outside the seed region, and the seed interaction
regions were low complexity G repeats. miR-608, similarly,
relied on low-complexity sequence recognition.
We selected four miRNAs for transfection into macro-
phages along with the TTP 3′UTR reporter construct:
miRs-145, -155, -361-3p, and -608. Despite numerous
predicted binding sites in the TTP 3′ UTR, miR-361-3p
did not occasion control of the 3′ UTR-containing re-
porter (Figure 4B). In contrast, transfection of miRs-608-,
155, and -145 reduced mean fluorescence intensity of the 3′
UTR construct compared with GFP alone by approximately
70%, 50%, and 40%, respectively (Figure 4B); this reduction
was significant for miR-608.
Differential expression of putative TTP-targeting miRNAs
in vivo
To evaluate the possible contributions of these miRNAs
to TTP regulation, we performed qPCR measurement of
miRs-145, -155, -361-3p, and -608 in brain. miR-361-3p
and miR-155 were upregulated over the course of infec-
tion (Figure 5). The substantial and significant increases in
the latter are consistent with the reported roles of miR-
155 in inflammation, and miR-155 reached its highest
levels in late-stage individuals that had severe CNS
disease. miR-608 was detected by PCR and appeared to
decline during late-stage disease (data not shown), but its
abundance in brain was quite low. Amplification of miR-
608 only after PCR cycle 35 in most samples diminished
confidence in the accuracy of measurement. In contrast,lignment representing the previously-described miR-29a/TTP 3′ UTR
nd a novel predicted interaction with miR-145. In each alignment, TTP
non-Watson-Crick “wobble” pairing of G and U is shown as ‘:’. B.
n the presence of the transfected synthetic miRNAs (HEK-293 T cells).
Figure 5 Longitudinal miRNA expression in SIV-infected brain. miRs-145, 361-3p, and -155 were measured in thalamus using stem-loop
RT-qPCR. Normalization was to U6 snRNA expression, and results are shown in comparison with the average of the control, uninfected (‘0’)
samples. Error bars are SEM. Significance of expression differences at each time point versus control was assesssed by Kruskal-Wallis test with
Dunn’s multiple comparison test: * (p < 0.05), ** (p < 0.01), *** (p < 0.001).
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late-stage disease that coincided with increased TTP
protein production during this phase (Figure 5). However,
although the median abundance values were significantly
different during each phase of infection, miR-145 down-
regulation was not significant according to a Kruskal
Wallis test. There was a negative correlation of miR-145
with TTP abundance across time points. This relationship
approached but did not reach statistical significance
at alpha = 0.05 (R = 0.31, p = 0.055). Nevertheless, these
results indicate that miR-145 may play a direct or indirect
role in TTP regulation, and that this possibility should be
investigated further.
Discussion
Tristetraprolin transcript was generally downregulated
over the course of SIV infection and CNS disease develop-
ment. Downregulation of TTP mRNA in the acute stage
of infection is consistent with the contemporaneous
upregulation of numerous cytokines. However, control of
cytokine production at the end of acute phase infection
[12] appears to involve mechanisms other than TTP
upregulation, since TTP levels remained comparatively
low during acute and latent infection. On average, during
late stage infection, TTP mRNA levels returned to the
levels found in uninfected control subjects, but this result
was driven largely by large increases of TTP transcript in
brain of subjects with the most severe CNS disease.
The mechanism of TTP downregulation likely involves
miRNAs. However, our confirmation and extension in
primary cells of a previous report that miR-29a exerted
regulation through the TTP 3′UTR was not accompan-
ied by observable negative correlations of miR-29a and
TTP expression in brain. Indeed, with the exception of
increased abundance in several late-stage subjects, par-
ticularly those with severe CNS disease, miR-29a expres-
sion did not change drastically during the course of
infection. We would like to note, however, that we couldnot perform longitudinal sampling on the same individ-
uals; because of interindividual variation, it remains pos-
sible that changes within the individual brain occurred
but could be observed only with much larger numbers
of subjects.
Since differences in miR-29a levels did not appear to
account for TTP regulation during SIV infection, several
additional miRNAs were investigated that, out of mul-
tiple candidates, exerted regulatory effects through the
TTP 3′ UTR. Quantitation of miRs-145, 155, 361-3p,
and -608 in brain and comparison of their abundance
with that of TTP indicated that miR-145 should be in-
vestigated further as a candidate for natural regulation
of TTP during SIV infection. The evidence did not sup-
port a consistent role for miRs-155, -361-3p, or the very
low-abundance miR-608 in TTP regulation. miR-608
did, however, appear to be a potentially effective regula-
tor of TTP in supraphysiologic quantitites.
It may be important to stress that absolute abundance
of a miRNA is not the only determinant of its involvement
in regulatory processes [41,42]. In addition to factors such
as sequestration and differential binding partners, the bal-
ance of all targeting miRNAs and all affected target—not
simply the level of a single miRNA—may be decisive in
determining the magnitude of observed regulation. Nu-
merous miRNAs with predicted MREs in the TTP 3′ UTR
are also predicted to target cytokines that are differentially
expressed during stages of infection in our model: miR-
145 (IL6, TNF-alpha, IFN-beta, and the chemokine
CCL2); miR-361-3p (IL10 and MIP1-alpha); miR-29 family
members (IFN-gamma, IL12p40); and miR-608 (IL6,
TNF-alpha, IL12p35 and -40, IL10, MIP1-alpha and -beta,
and CCL2).
We thus posit the following model. During acute in-
fection, TTP transcript abundance is slightly reduced.
This likely occurs at the transcriptional level, since ERK
activation, which occurs during early viral replication
[43], including in our model [44], downregulates TTP
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increased turnover of the TTP mRNA cannot be ruled
out. At the same time, miRNA-mediated control of TTP
translation is relieved by a combination of mechanisms in
the broader context of antiviral innate immune responses.
These may include both downregulation of some targeting
miRNAs and greatly increased transcription of mRNAs
of cytokines and other factors produced during the
innate immune responses. These transcripts would act as
“sponges” for miRNAs that also target TTP. As a result,
TTP protein levels could be maintained or even rise
despite lower levels of transcript, and this situation would
be exacerbated with increasing transcription. The overall
abundance of all mRNA targets of TTP-targeting miRNAs
would determine the extent to which miRNA levels could
affect TTP production. The explosion of dysregulated
cytokine transcripts during progression to CNS disease
would thus explain why even greatly increased levels of
TTP targeters such as miR-155—or, in some individuals,
miR-29a—would have little or no effect on TTP. Carefully
integrated systems biology experiments and new ap-
proaches for detecting miRNA-target antagonism patterns
[46-48] will help to address these issues in future studies.
Apart from the remaining questions regarding mecha-
nisms of TTP regulation, our results show that TTP
transcript abundance alone cannot explain changes in
cytokine mRNA levels during progression to lentiviral
CNS disease, and that increases in TTP are in fact asso-
ciated with disease development. During late-stage SIV
CNS disease in our model, both TTP and its targets, in-
cluding inflammatory cytokines, are upregulated in brain
of individuals with severe encephalitis. It would thus
appear that although TTP may influence cytokine levels
during early infection, and while the protein likely con-
tinues to exert a dampening effect throughout infection,
increases in TTP are insufficient to control inflammation
during late stage disease. Preliminary results indicate
that this may be due to a marked increase in phosphory-
lated TTP [49] during progression to disease (JL and
KWW, unpublished observations). Since phosphorylated
forms of the protein are known to have impaired ability
to cause mRNA decay [36,50], the prevalent form of the
protein during late-stage infection may not effectively
regulate transcripts of inflammatory mediators.
The finding of upregulated but partly ineffective TTP
in disease is also consistent with reports on TTP in sev-
eral diseases and models. In an interesting recent study
with some parallels to this work, Zhang et al reported
that TTP was upregulated in endothelial cells in contact
with atherosclerotic lesions [51]. Also, in rheumatoid
arthritis upregulated TTP is found in cells involved in
pathogenesis [52] and may be a marker of severe disease
[53], in part because of production stimulated by the
TTP target TNF. Although the complete absence ofTTP (knockout mice) is associated with uncontrolled in-
flammatory responses [20,54-56] and TTP influences cyto-
kine levels in cell culture models, there are conflicting
reports on whether TTP and TNF levels are correlated in
rheumatoid arthritis patient samples [34,53]. Exposure of
mouse brain to hypertonic insult resulted in upregulation
of both TTP and TNF [57]. In some cases, then, the normal
TTP anti-inflammatory mechanism, although duly acti-
vated, cannot completely or on its own stem the rising in-
flammatory tide of disease- or injury-related dysregulation.
Indeed, TTP can promote apoptosis independently of
its effects on mRNA stability, an effect that has
prompted the label of “anti-oncogene” [35,58,59]. Thus,
the high levels of TTP observed in macaque brain dur-
ing late stage lentiviral infection may not be protective,
but may instead contribute to CNS disease. Increasing
the levels of TTP to enable the mRNA-destabilizing
activity of this RNA binding protein—for example,
through the use of inhibitors of anti-TTP miRNAs [24]—
is an attractive therapeutic possibility in cancers [24], ath-
erosclerosis [51], and perhaps other conditions. Models
such as ours may play an important role in investigating
the possibly deleterious effects of increased TTP in the
CNS during lentiviral infection.
Conclusions
TTP mRNA levels were modulated during SIV infection,
but large fold upregulation of TTP was insufficient to
control dysregulated CNS cytokine expression during
late-stage disease. We also confirmed TTP as a target of
miR-29a, but found that higher miR-29a expression in
brain was not associated with reduced TTP abundance.
The results presented here are consistent with targeting
of TTP by additional miRNAs and the existence of a
complex interaction network governing TTP, miRNA,
and cytokine expression. Additional research is needed
to characterize this network more fully, including the
contributions of protein levels and post-translational
modifications of TTP. Finally, the possibly deleterious
effects of increased levels of TTP should be assessed
carefully along with any investigation of TTP-altering
therapies as a strategy to control cytokine deregulation
in retrovirus-associated CNS disease.
Methods
Animal studies and ethics statement
No new animal studies were conducted for this project.
Archived samples were from previous studies involving
dual-inoculation of Macaca nemestrina with an immuno-
suppressive SIV swarm and a neurotropic clone [14]. All
animal studies were approved by the Johns Hopkins Uni-
versity Institutional Animal Care and Use Committee and
conducted in accordance with the Weatherall Report, the
Guide for the Care and Use of Laboratory Animals (NIH
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Animal Welfare Act.
Cell culture
HEK-293 T cells were cultured in D10 media (DMEM, 10%
fetal bovine serum, 2 mM L-Glutamine, 10 mM HEPES.
Cells were passaged upon reaching 80% confluency,
approximately every 3 days.
Human macrophages were differentiated from mono-
cytes in peripheral blood mononuclear cells (PBMCs)
that were isolated by standard Percoll protocol, as
described previously [60]. PBMCs were cultured in
macrophage differentiation medium with 20% serum
[MDM20: Dulbecco’s modified Eagle’s medium (DMEM,
Invitrogen), 20% human serum (GemCell), 2 mM L-Glu-
tamine (Sigma), 10 mM HEPES (Gibco), 10 mM sodium
pyruvate (Sigma), 50 ng/ml M-CSF (R&D), and 2 mg/ml
Gentamicin (Gibco)] for one week, with a half-volume re-
feeding at three days post-plating. After seven days, super-
natants were removed and adherent macrophages were
washed with PBS. Medium was replaced with MDM10
(MDM with 10% human serum).
Reporter plasmid cloning
The TTP 3′UTR was amplified from cDNA using
primers 5′-GGA CTC AGA TCT CGA GCA AAG TGA
C 3′ and 5′ – GAT CCC GGG CCC GCG GTA CCG
ATC C-3′ that contained Kpn1 and XhoI restriction
sites, respectively. The PCR product was sequenced
(GeneWiz), verified against the Ensembl Genome data-
base, and cloned by TOPO cloning kit (Invitrogen). The
pEGFP-TTP UTR construct was made by subcloning
the TTP3′ UTR into the pEGFP-C1 plasmid (Clontech)
using the same restriction enzymes.
Transfections
HEK-293 T cells were reverse transfected by seeding in
antibiotic-free medium onto 96-well plates containing
Lipofectamine 2000 (Invitrogen) complexes containing
50 nM synthetic miRNA mimics, miRNA antagonists, or
control RNAs (Qiagen) and 150 ng reporter plasmid
DNA. Medium was removed, cells were washed with
PBS, and fresh medium was added after four hours.
Human monocyte-derived macrophages were trans-
fected with 100 nM synthetic RNAs using Lipofectamine
2000 in medium without antibiotics. Transfection com-
plexes were removed, and cells were washed with PBS and
re-fed with fresh MDM10 after 4 hours.
RNA isolation
RNA was isolated from cells using TRIzol reagent
(Invitrogen) per manufacturer’s protocol. Macaque thal-
amus tissue was homogenized using bead Lysing Matrix
D (MP Biomedicals) and TRIzol.Flow cytometry
HEK-293 T cells transfected with GFP-containing plasmid
DNA, RFP transfection normalization control, and syn-
thetic RNAs were harvested 24 hours post-transfection via
trypsinization. Flow cytometry was performed with a BD
FACSCalibur instrument. Analysis was performed with
Flowjo 9.1 software (Flowjo).
Quantitative RT-PCR
Reverse transcription quantitative real-time PCR for
TTP messenger RNA was performed using macaque
brain RNA. Random primers were used to reverse tran-
scribe RNA into cDNA. TTP cDNA was then amplified
using the primers 5′-GGC GAC TCC CCA TCT TCA
AT-3′ and 5′CAG TGC AAC AGA CGT GGC TC-3′.
Amplification was monitored in real time with a HEX-
conjugated probe (5′-TCT GAG TGA CAA GTG ACT
GCC CGG TCA G-3′). All primers and probes were
from IDT. Fold changes in induction were analyzed
using the delta-delta-C(t) method with comparison to
18S rRNA as described previously [12]. Cytokine mea-
surements for the same samples were retrieved from our
database and were made as described previously [12].
MicroRNA RT-qPCR was performed using the stem-
loop RT primer/Taqman microRNA PCR system (Applied
Biosystems) [61]. The suggested protocol was followed as
previously described [62] with the following alterations.
Reverse transcription primer amount was reduced to 1.5
ul per reaction, and reverse transcription reactions were
multiplexed. Real-time probe volume was reduced to 0.5
ul per reaction. Fold changes in induction were analyzed
using the delta-delta-C(t) method with comparison to the
small RNA U6 (as depicted) or, with similar results, to the
geometric mean of six relatively invariant small RNAs
(data not shown). For both mRNA and miRNA RT-qPCR,
amplification reactions were performed on either the iQ5
or the Chromo4 optical system (BioRad).
Target predictions
A Perl program described previously [13] was used to
combine the RNAhybrid [63], TargetScan [64], and Mi-
Randa [65] target prediction algorithms, assigning a score
to candidate macaque miRNA/3′ UTR pairs by the num-
ber of programs predicting interaction and the number of
calls per 3′ UTR.
Additional file
Additional file 1: Figure S1. Effect of synthetic mir-29a and antagonists
on TTP protein production in primary macrophages. Monocyte-derived
macrophages at day seven of differentiation were transfected with miR-
29a mimic or antagonist, or control mimics or antagonists. Protein was
harvested at least 24 hours after transfection and subjected to Western
blotting. TTP band intensities were normalized to those of beta-III tubulin.
Only a slight reduction of TTP protein was observed with addition of
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http://www.molecularbrain.com/content/6/1/40exogenous miR-29a, but a four-fold increase resulted from transfection of
miR-29a antagonist. Note that the three middle lanes on the protein blot
(not shown in the quantitation graph) represent experiments with miRNA
mimics that were unrelated to miR-29a.
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